<DOC>
	<DOC>NCT01932385</DOC>
	<brief_summary>Due to the HBV and HCV infection, about 55% hepatocellular carcinoma patients happened in China. Among them, only 10% patients can be diagnosed in early stage. Sorafenib increased PFS and OS in advanced hepatocellular carcinoma patients with liver function of Child-Pugh class A patients, but the result for Child-Pugh class B patients is unclear.</brief_summary>
	<brief_title>Sorafenib in Liver Function Impaired Advanced Hepatocellular Carcinoma</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma, Hepatocellular</mesh_term>
	<mesh_term>Liver Neoplasms</mesh_term>
	<mesh_term>Sorafenib</mesh_term>
	<mesh_term>Niacinamide</mesh_term>
	<criteria>pathological or cytological confirmed advanced hepatocellular carcinoma 18 years to 80 years liver function ChildPugh class B BCLC stage B or C estimated life time 2 months or longer previous target therapy allergy to Sorafenib Uncontrolled Bleeding or diarrhea eligible for locoregional treatment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>Sorafenib</keyword>
	<keyword>Hepatocellular carcinoma</keyword>
	<keyword>Best supportive care</keyword>
	<keyword>Survival</keyword>
</DOC>